doi:10.1152/physrev.00020.2003
As coverage for GLP-1s increases, self-funded employers and health plans already grappling with costs associated with GLP-1 medications will face heightened challenges
Acknowledgements The authors would like to acknowledge Dr
Contrast products: Iohexol, Iopamidol, Iodixanol, Iopromide, Ioversol, Iomepride, Gadopentate meglumine, Gadoterate, etc
[3][6] NLEM 2022 already emphasises the growing burden of diabetes and the need for key diabetes drugs in public systems, and official documents acknowledge GLP-1 RAs as important options.[15] If liraglutide and semaglutide formulations used for diabetes are eventually brought under price control, MRPs could drop by another 2030% beyond current generic competition, especially where innovator prices remain high